CRISPR Therapeutics AG (STU:1CG) Cyclically Adjusted Book per Share: €15.06 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1CG CRISPR Therapeutics AG STU:1CG
40 GF Score
Price €44.28
GF Value €3.17
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Cyclically Adjusted Book per Share?

CRISPR Therapeutics AG STU:1CG -0.36% 40 Cyclically Adjusted Book per Share is €15.06 as of Mar. 2026. GuruFocus rates STU:1CG with a GF Score™ of 40/100 and a GF Value™ of €3.17 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

CRISPR Therapeutics AG's adjusted book value per share for the three months ended in Mar. 2026 was €16.284. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €15.06 for the trailing ten years ended in Mar. 2026.

During the past 12 months, CRISPR Therapeutics AG's average Cyclically Adjusted Book Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-15), CRISPR Therapeutics AG's current stock price is €44.275. CRISPR Therapeutics AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €15.06. CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio of today is 2.94.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of CRISPR Therapeutics AG was 4.31. The lowest was 2.00. And the median was 3.13.


CRISPR Therapeutics AG  (STU:1CG) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=44.275/15.06
=2.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of CRISPR Therapeutics AG was 4.31. The lowest was 2.00. And the median was 3.13.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


CRISPR Therapeutics AG Cyclically Adjusted Book per Share Related Terms


CRISPR Therapeutics AG Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Cyclically Adjusted Book per Share Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 15.45

CRISPR Therapeutics AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.58 14.31 14.51 15.45 15.06

STU:1CG vs ORKA, TVTX, MANE: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio falls into.


STU:1CG
40GF Score
CRISPR Therapeutics AG STU:1CG
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CRISPR Therapeutics AG's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=16.284/108.0600*108.0600
=16.284

Current CPI (Mar. 2026) = 108.0600.

CRISPR Therapeutics AG Quarterly Data

Book Value per Share CPI Adj_Book
201606 3.030 100.088 3.271
201609 -1.401 99.604 -1.520
201612 5.557 99.380 6.042
201703 5.053 100.040 5.458
201706 4.397 100.285 4.738
201709 3.672 100.254 3.958
201712 3.910 100.213 4.216
201803 5.044 100.836 5.405
201806 4.822 101.435 5.137
201809 6.937 101.246 7.404
201812 6.648 100.906 7.119
201903 6.386 101.571 6.794
201906 6.082 102.044 6.441
201909 9.738 101.396 10.378
201912 13.910 101.063 14.873
202003 13.170 101.048 14.084
202006 12.626 100.743 13.543
202009 16.153 100.585 17.353
202012 18.508 100.241 19.952
202103 20.026 100.800 21.468
202106 28.407 101.352 30.287
202109 27.935 101.533 29.731
202112 27.582 101.776 29.285
202203 26.340 103.205 27.579
202206 25.426 104.783 26.221
202209 25.221 104.835 25.997
202212 22.550 104.666 23.281
202303 21.968 106.245 22.343
202306 21.118 106.576 21.412
202309 20.383 106.570 20.668
202312 21.570 106.461 21.894
202403 22.599 107.355 22.747
202406 21.639 107.991 21.653
202409 20.479 107.468 20.592
202412 21.520 107.128 21.707
202503 19.592 107.722 19.653
202506 16.787 108.075 16.785
202509 17.390 107.710 17.447
202512 17.115 107.200 17.252
202603 16.284 108.060 16.284

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €15.06 mean?
CRISPR Therapeutics AG (STU:1CG) has a Cyclically Adjusted Book per Share of €15.06 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Cyclically Adjusted Book per Share too high?
CRISPR Therapeutics AG's current Cyclically Adjusted Book per Share is €15.06. Overall, CRISPR Therapeutics AG has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Cyclically Adjusted Book per Share compare to ORKA and TVTX?
CRISPR Therapeutics AG's Cyclically Adjusted Book per Share of €15.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Cyclically Adjusted Book per Share is €15.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (STU:1CG) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.17, compared to a current price of €44.28 — trading 1296.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is €15.06. CRISPR Therapeutics AG's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For CRISPR Therapeutics AG (STU:1CG), the current Cyclically Adjusted Book per Share is €15.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (STU:1CG) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of €44.28 is trading 1296.7% above its estimated GF Value™ of €3.17. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for STU:1CG:

  • Cyclically Adjusted Book per Share: €15.06
  • GF Value™: €3.17 vs. price of €44.28 (1296.7% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the STU:1CG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
40GF Score

Get the complete analysis for STU:1CG

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€44.28
Price
€3.17
GF Value